The Grattan Institute has released a landmark report, Future Pharmacy: A Better Deal for Patients and Taxpayers. This report on Australian Pharmacy Reform argues that the current framework is a “shakedown” that benefits pharmacy owners far more than patients and taxpayers.
According to the report, structural reforms are urgently required to improve market transparency, lower medicine costs, and dismantle anti-competitive protections. While the Australian Medical Association (AMA) has strongly welcomed the findings, the Pharmacy Guild Australia has vigorously disputed the report, defending the existing structure.
AMA President Dr. Danielle McMullen welcomed the report, noting the AMA has long fought to scrap “archaic” location rules.
“The restrictions on pharmacy ownership and location are anti-competitive and undermine patients’ access to medicines and services,” Dr. McMullen stated, endorsing greater transparency and the integration of pharmacists into general practices.
Why Is Grattan Institute’s Report on Australian Pharmacy Reform Needed?
The Grattan Institute highlights that the Australian community pharmacy networks cost patients and the federal government nearly AU$4 billion annually in dispensing and administrative fees. Despite this massive public expenditure, the highly critical report on Australian Pharmacy Reform points out that the Community Pharmacy Agreement (CPA) is negotiated entirely behind closed doors. These agreements occur directly between the federal government and the powerful Pharmacy Guild Australia, completely excluding patients and independent health advocates.
Simon Blacker, the Guild’s national vice president, argued that existing rules prevent corporate consolidation and ensure equitable access across 330 rural towns where a pharmacy is the only healthcare option. “Medicines are not ordinary retail products, and community pharmacies should continue to operate as healthcare providers first and foremost,” Blacker stated.
Researchers state that Australian pharmacy policy has long lacked independent oversight and public evidence. This lack of transparency has allowed pharmacy profits to more than double over the past decade while limiting direct consumer benefits, creating an insulated system that is insufficiently evidence-based.
Key Problems Identified in Australia’s Pharmacy System
To explain why comprehensive Australian healthcare reform is required, the report exposes three critical systemic issues.
1. High Dispensing Fees
The Grattan Institute report argues that existing dispensing fees (the fees paid to a pharmacy to process and prepare a script) are inflated and do not reflect actual dispensing costs. Combined with additional administrative and handling payments, pharmacies are routinely reimbursed well above the true cost of the medicines. Revising these pricing structures could unlock hundreds of millions of dollars in taxpayer savings.
2. Limited Competition
Strict regulation on pharmacy ownership and pharmacy location prevents new competitors from entering the market. Current laws restrict individuals from owning more than five pharmacies and place heavy barriers against establishing pharmacies in supermarkets.
Furthermore, strict regulations penalize or discourage pharmacies from offering meaningful discounts on scripts, keeping prescription medicine prices artificially high.
3. Transparency Concerns
The Pharmacy Guild Australia wields immense political influence, heavily backed by $2.5 million in political donations over the last five years. The report on pharmacy agreements stresses that this political clout has allowed a single lobby group to dictate public health funding.
Analysts are calling for an immediate end to backroom deals, recommending that independent authorities, patients, and frontline pharmacists be included in future policy decisions.
Major Pharmacy Reform Recommendations In Grattan Report
The report on Australian Pharmacy Reform outlines a series of structural shifts to update the sector.
1. Replace Backroom Negotiations
- Independent Authority: Shift pricing power to an independent body, such as the Independent Health and Aged Care Pricing Authority (IHACPA).
- Public Evidence: Require all funding models to be justified by transparent, public data rather than political bargaining.
2. Modernize Pharmacy Funding
- Streamlined Fees: Eliminate unjustified add-on fees, including discretionary patient surcharges and specific recording fees.
- Cost-Based Remuneration: Reset the baseline dispensing fee to reflect real-world operational costs.
3. Increase Competition
- Abolish Protections: Remove outdated regulation on pharmacy ownership and pharmacy location.
- Unleash Retail Choice: Permit community pharmacies to operate inside major supermarkets and allow unrestricted discounting on all medicines.
4. Improve Pharmacy Services
- GP Integration: Invest $80 million to embed non-dispensing pharmacists directly within general practice clinics and Aboriginal Health Organisations.
- Scope of Practice: Fund pharmacists to prescribe treatments for uncomplicated urinary tract infections (UTIs) where safe and clinically supported.
How The Australian Pharmacy Reforms Could Affect Patients
If the recommendations from the report on Australian Pharmacy Reform are adopted, consumers would see immediate structural benefits:
- Lower Prescription Costs: Increased competition and legal discounting would directly drop prescription medicine prices.
- Greater Choice and Access: Allowing pharmacies in supermarkets means longer opening hours and more convenient locations.
- Better Integrated Care: Shifting pharmacists into GP clinics ensures medication expertise is directly tied to a patient’s primary doctor.
To protect regional areas, the report recommends replacing blanket protections with targeted financial support and rigorous monitoring by the Australian Competition and Consumer Commission (ACCC) to stop corporate monopolies.
What Happens Next In Australian Healthcare?
The Grattan Institute’s report on Australian Pharmacy Reform, Future Pharmacy: A Better Deal for Patients and Taxpayers, delivers a clear mandate: Australia’s pharmacy framework must prioritize patients and taxpayers over commercial owners through transparency, cost-based funding, and open competition.
The federal government now faces the challenge of balancing affordability with rural healthcare access. As policymakers look toward drafting the next Community Pharmacy Agreement, this Report will help create a balanced approach that lowers the cost of vital medicines without compromising the equitable, high-quality care that Australians rely on.
